Akila Boozer
Family · Greenwood, SCNPI 1316594724
Payments from drug & device makers
Across 524 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$994
- Teva Pharmaceuticals USA, Inc.$947
- plus $2K from 16 others
What the payments were for
- Food & beverage$8,38999%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 70 | $1,332 |
| Otsuka America Pharmaceutical, Inc. | 72 | $1,204 |
| AbbVie | 94 | $1,134 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 65 | $1,055 |
| Johnson & Johnson | 48 | $994 |
| Teva Pharmaceuticals USA, Inc. | 82 | $947 |
| Alkermes, Inc. | 31 | $644 |
| E.r. Squibb & Sons, L.L.C. | 16 | $309 |
| Supernus Pharmaceuticals, Inc. | 7 | $122 |
| Sunovion Pharmaceuticals Inc. | 10 | $114 |
| Lundbeck LLC | 5 | $108 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| Ironshore Pharmaceuticals Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Tris Pharma Inc | 2 | $46 |
| Indivior Inc. | 2 | $43 |
| Bristol Myers Squibb | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$122
- ABILIFY MAINTENA$121
- ABILIFY ASIMTUFII$121
- INGREZZA$114
- VRAYLAR$113
- SPRAVATO$108
How this compares
$8,448 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 202 | $628,855 |
| IngrezzaValbenazine Tosylate | 30 | $240,971 |
| Abilify MaintenaAripiprazole | 73 | $217,940 |
| RexultiBrexpiprazole | 59 | $117,939 |
| AustedoDeutetrabenazine | 15 | $110,798 |
| Invega TrinzaPaliperidone Palmitate | 13 | $82,212 |
| UzedyRisperidone | 20 | $63,854 |
| AristadaAripiprazole Lauroxil | 19 | $62,557 |
| CaplytaLumateperone Tosylate | 36 | $60,046 |
| VraylarCariprazine Hcl | 42 | $60,039 |
| FanaptIloperidone | 12 | $26,573 |
| Risperdal ConstaRisperidone Microspheres | 15 | $26,271 |
| LatudaLurasidone Hcl | 11 | $24,265 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $20,154 |
| Paliperidone ErPaliperidone | 84 | $16,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $994 | $737,339230 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,204 | $335,878132 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,332 | $240,97130 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $947 | $174,65235 claims |
| Alkermes, Inc.Aristada | $644 | $62,55719 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,055 | $60,04636 claims |
| AbbVieVraylar | $1,134 | $60,03942 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $106 | $26,57312 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $114 | $24,26511 claims |
| Axsome Therapeutics, Inc.Auvelity | $19 | $20,15411 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $18 | $9,38220 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $64 | $7,37920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Greenwood
- Jill ShirleyGreenwood$11K
- Kelly CrawfordGreenwood$11K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.